http://www.forbes.com/sites/larryhusten/
Larry Husten - Cardiobrief - ForbesLarry Husten's stories. Cardiobrief: I'm a medical journalist covering cardiology news.http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=400&amp;d=http%3A%2F%2F1.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D400&amp;r=Ghttp://www.forbes.com/sites/larryhusten/2015/03/03/no-drinking-coffee-wont-save-your-life-or-prevent-heart-attacks/
No, Drinking Coffee Won't Save Your Life Or Prevent Heart AttacksOnce again the media has swallowed the bait hook, line, and sinker. Following the publication of a a new study in the journal Heart last night, hundreds of news reports have now appeared extolling the miraculous benefits of coffee. Here's just one typical headline from the Los Angeles Times: "Another reason to drink coffee: It's [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/03/03/no-drinking-coffee-wont-save-your-life-or-prevent-heart-attacks/Tue, 3 Mar 2015 09:50:00 -0500Once again the media has swallowed the bait hook, line, and sinker. Following the publication of a a new study in the journal Heart last night, hundreds of news reports have now appeared extolling the miraculous benefits of coffee. Here's just one typical headline from the Los Angeles Times: "Another reason to drink coffee: It's [...]http://www.forbes.com/sites/larryhusten/2015/03/02/hospitals-like-vampires-want-your-blood/
Hospitals, Like Vampires, Want Your BloodAnyone who has been in the hospital, either as a patient or a healthcare provider, is keenly aware that hospitals perform a lot of tests. It has even been suggested that some of those tests may not be necessary. Now a new study published in the Annals of Thoracic Surgery sheds light on [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/03/02/hospitals-like-vampires-want-your-blood/Mon, 2 Mar 2015 08:00:00 -0500Anyone who has been in the hospital, either as a patient or a healthcare provider, is keenly aware that hospitals perform a lot of tests. It has even been suggested that some of those tests may not be necessary. Now a new study published in the Annals of Thoracic Surgery sheds light on [...]http://www.forbes.com/sites/larryhusten/2015/02/25/new-york-city-ebola-doctor-slams-media-and-governors-christie-and-cuomo/
New York City Ebola Doctor Slams Media And Governors Christie And CuomoThe response in the US to the Ebola crisis last year brought out the worst in the media and our politicians. By comparison, our response to the recent measles crisis-- by no means a model for public health communication-- had the sophistication and intelligence of a debate at the Oxford Union. One of the chief victims [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/25/new-york-city-ebola-doctor-slams-media-and-governors-christie-and-cuomo/Wed, 25 Feb 2015 17:06:00 -0500The response in the US to the Ebola crisis last year brought out the worst in the media and our politicians. By comparison, our response to the recent measles crisis-- by no means a model for public health communication-- had the sophistication and intelligence of a debate at the Oxford Union. One of the chief victims [...]http://www.forbes.com/sites/larryhusten/2015/02/24/common-pain-drugs-linked-to-more-problems-after-a-heart-attack/
Common Pain Drugs Linked To More Problems After A Heart AttackThe cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and diclofenac has been the subject of considerable uncertainty and controversy. Now a new study published in JAMA raises specific concerns about the safety of these drugs in the highly vulnerable population of people who have had a recent heart attack. Using data from [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/24/common-pain-drugs-linked-to-more-problems-after-a-heart-attack/Tue, 24 Feb 2015 13:18:00 -0500The cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and diclofenac has been the subject of considerable uncertainty and controversy. Now a new study published in JAMA raises specific concerns about the safety of these drugs in the highly vulnerable population of people who have had a recent heart attack. Using data from [...]http://www.forbes.com/sites/larryhusten/2015/02/23/everybody-into-the-sauna/
Everybody Into The Sauna?Spending more time in the sauna may lead to a longer and healthier life-- at least if you live in Finland, according to a new study published in JAMA Internal Medicine. Finnish researchers analyzed data from the Kuopio Ischemic Heart Disease Risk Factor Study. The new analysis focused on 2,315 middle-aged men who had [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/23/everybody-into-the-sauna/Mon, 23 Feb 2015 11:13:00 -0500Spending more time in the sauna may lead to a longer and healthier life-- at least if you live in Finland, according to a new study published in JAMA Internal Medicine. Finnish researchers analyzed data from the Kuopio Ischemic Heart Disease Risk Factor Study. The new analysis focused on 2,315 middle-aged men who had [...]http://www.forbes.com/sites/larryhusten/2015/02/19/medtronic-and-boston-scientific-plan-to-resume-blood-pressure-trials-this-year/
Medtronic And Boston Scientific Plan To Resume Blood Pressure Trials This YearMedtronic and Boston Scientific have announced plans to start phase 2 clinical trials this year for their updated renal denervation catheters. The once promising new technology is intended to treat hypertension unresponsive to drug therapy. The failure last year of Medtronic's Symplicity HTN-3, the first large pivotal trial to rigorously test renal denervation, [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/19/medtronic-and-boston-scientific-plan-to-resume-blood-pressure-trials-this-year/Thu, 19 Feb 2015 15:56:00 -0500Medtronic and Boston Scientific have announced plans to start phase 2 clinical trials this year for their updated renal denervation catheters. The once promising new technology is intended to treat hypertension unresponsive to drug therapy. The failure last year of Medtronic's Symplicity HTN-3, the first large pivotal trial to rigorously test renal denervation, [...]http://www.forbes.com/sites/larryhusten/2015/02/18/no-the-new-cholesterol-drugs-from-sanofi-and-amgen-arent-going-to-cost-150-billion-a-year/
No, The New Cholesterol Drugs From Sanofi And Amgen Aren't Going To Cost $150 Billion A YearIn an article on the Health Affairs blog 4 CVS executives speculate that the new cholesterol lowering PCSK9 inhibitors from Amgen and Sanofi might achieve yearly sales of $150 billion or even higher. I think these numbers are a bit silly. But first let's take a look at their extremely bullish case: Simple Math... The CVS authors calculate that [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/18/no-the-new-cholesterol-drugs-from-sanofi-and-amgen-arent-going-to-cost-150-billion-a-year/Wed, 18 Feb 2015 16:07:00 -0500In an article on the Health Affairs blog 4 CVS executives speculate that the new cholesterol lowering PCSK9 inhibitors from Amgen and Sanofi might achieve yearly sales of $150 billion or even higher. I think these numbers are a bit silly. But first let's take a look at their extremely bullish case: Simple Math... The CVS authors calculate that [...]http://www.forbes.com/sites/larryhusten/2015/02/16/very-simple-high-fiber-diet-stands-up-to-american-heart-association-diet/
Very Simple High-Fiber Diet Stands Up To American Heart Association DietDiets notoriously fail to help people lose a lot of weight. One problem is that most diets include a broad range of restrictions and guidelines that many people find difficult to follow. Another problem is that negative recommendations may have unintended consequences, such as low-fat recommendations leading to increased consumption [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/16/very-simple-high-fiber-diet-stands-up-to-american-heart-association-diet/Mon, 16 Feb 2015 17:05:00 -0500Diets notoriously fail to help people lose a lot of weight. One problem is that most diets include a broad range of restrictions and guidelines that many people find difficult to follow. Another problem is that negative recommendations may have unintended consequences, such as low-fat recommendations leading to increased consumption [...]http://www.forbes.com/sites/larryhusten/2015/02/16/more-guideline-controversy-the-tricky-business-of-calculating-cardiovascular-risk/
More Guideline Controversy: The Tricky Business Of Calculating Cardiovascular RiskCalculating cardiovascular risk has become a central and highly controversial component of cardiovascular guidelines. Now a study in the Annals of Internal Medicine finds that most of the commonly employed tools seriously overestimate the risk of people today. Researchers used data from 4,227 people enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA) between 2000 and [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/16/more-guideline-controversy-the-tricky-business-of-calculating-cardiovascular-risk/Mon, 16 Feb 2015 17:01:00 -0500Calculating cardiovascular risk has become a central and highly controversial component of cardiovascular guidelines. Now a study in the Annals of Internal Medicine finds that most of the commonly employed tools seriously overestimate the risk of people today. Researchers used data from 4,227 people enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA) between 2000 and [...]http://www.forbes.com/sites/larryhusten/2015/02/11/three-trials-show-benefits-of-thrombectomy-in-stroke-patients/
Clot Extractors Shown Beneficial In Stroke PatientsThree new studies offer important additional evidence that early treatment with current thrombectomy devices that extract clots from blood vessels in the brain can lead to improved outcomes in carefully selected stroke patients. The trials were stopped early based on efficacy following positive findings last year from another trial, MR CLEAN. [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/11/three-trials-show-benefits-of-thrombectomy-in-stroke-patients/Wed, 11 Feb 2015 16:07:00 -0500Three new studies offer important additional evidence that early treatment with current thrombectomy devices that extract clots from blood vessels in the brain can lead to improved outcomes in carefully selected stroke patients. The trials were stopped early based on efficacy following positive findings last year from another trial, MR CLEAN. [...]http://www.forbes.com/sites/larryhusten/2015/02/10/new-us-guidelines-will-lift-limits-on-dietary-cholesterol/
New U.S. Guidelines Will Lift Limits On Dietary CholesterolThe influential Dietary Guidelines Advisory Committee has recommended that limitations on dietary cholesterol be removed from the upcoming 2015 edition of Dietary Guidelines for Americans. Recommendations to reduce dietary cholesterol have been a mainstay of the USDA and other guidelines for many years, starting with guidelines from the American Heart Association in [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/10/new-us-guidelines-will-lift-limits-on-dietary-cholesterol/Tue, 10 Feb 2015 19:35:00 -0500The influential Dietary Guidelines Advisory Committee has recommended that limitations on dietary cholesterol be removed from the upcoming 2015 edition of Dietary Guidelines for Americans. Recommendations to reduce dietary cholesterol have been a mainstay of the USDA and other guidelines for many years, starting with guidelines from the American Heart Association in [...]http://www.forbes.com/sites/larryhusten/2015/02/10/another-study-raises-questions-about-blood-pressure-guidelines/
Another Study Raises Questions About Blood Pressure GuidelinesAlthough the general benefits of lowering high blood pressure are widely accepted, there has been intense debate over specific goals for treatment and the threshold at which therapy should be initiated. A large new meta-analsysis published in JAMA helps shed lights on this important controversy. UK and Australian researchers analyzed the effect of lowering [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/10/another-study-raises-questions-about-blood-pressure-guidelines/Tue, 10 Feb 2015 11:00:00 -0500Although the general benefits of lowering high blood pressure are widely accepted, there has been intense debate over specific goals for treatment and the threshold at which therapy should be initiated. A large new meta-analsysis published in JAMA helps shed lights on this important controversy. UK and Australian researchers analyzed the effect of lowering [...]http://www.forbes.com/sites/larryhusten/2015/02/09/new-heart-drug-from-novartis-will-it-raise-the-risk-of-alzheimers-disease/
New Heart Drug From Novartis: Will It Raise The Risk of Alzheimer's Disease?LCZ696 is a heart failure drug from Novartis that many observers think will gain FDA approval later this year and go on to become a blockbuster. Perhaps the biggest obstacle to the drug's success is the fear that it might raise the risk of Alzheimer's disease. Now a new article in [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/09/new-heart-drug-from-novartis-will-it-raise-the-risk-of-alzheimers-disease/Mon, 9 Feb 2015 08:57:00 -0500LCZ696 is a heart failure drug from Novartis that many observers think will gain FDA approval later this year and go on to become a blockbuster. Perhaps the biggest obstacle to the drug's success is the fear that it might raise the risk of Alzheimer's disease. Now a new article in [...]http://www.forbes.com/sites/larryhusten/2015/02/05/novel-device-offers-hope-for-heart-patients-with-no-alternatives/
Novel Device Offers Hope For Heart Patients With No AlternativesAn entirely predictable consequence of medical progress is the growing number of heart patients with persistent and symptomatic angina who have run out of treatment options. A small study published in the New England Journal of Medicine raises the possibility that a new and novel device one day may provide them some relief. The experimental [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/05/novel-device-offers-hope-for-heart-patients-with-no-alternatives/Thu, 5 Feb 2015 09:00:00 -0500An entirely predictable consequence of medical progress is the growing number of heart patients with persistent and symptomatic angina who have run out of treatment options. A small study published in the New England Journal of Medicine raises the possibility that a new and novel device one day may provide them some relief. The experimental [...]http://www.forbes.com/sites/larryhusten/2015/02/03/no-too-much-jogging-probably-wont-kill-you/
No, Too Much Jogging Probably Won't Kill YouOnce again lazy health journalists have fallen down on the job and performed a disservice to the public. The new outrage: a multitude of media reports about a small study on the effect of jogging on mortality. Here are just a few headlines, published minutes after the study was published in the Journal [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/02/03/no-too-much-jogging-probably-wont-kill-you/Tue, 3 Feb 2015 09:56:00 -0500Once again lazy health journalists have fallen down on the job and performed a disservice to the public. The new outrage: a multitude of media reports about a small study on the effect of jogging on mortality. Here are just a few headlines, published minutes after the study was published in the Journal [...]http://www.forbes.com/sites/larryhusten/2015/01/29/study-tests-high-blood-pressure-control-during-pregnancy/
Study Tests High Blood Pressure Control During PregnancyHigh blood pressure during pregnancy is increasingly common, largely due to older age and obesity. Although there is widespread agreement that hypertension in these women should be treated when it is high enough to raise the risk of stroke, there is little agreement about whether or how to treat mild [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/29/study-tests-high-blood-pressure-control-during-pregnancy/Thu, 29 Jan 2015 13:50:00 -0500High blood pressure during pregnancy is increasingly common, largely due to older age and obesity. Although there is widespread agreement that hypertension in these women should be treated when it is high enough to raise the risk of stroke, there is little agreement about whether or how to treat mild [...]http://www.forbes.com/sites/larryhusten/2015/01/28/fda-approves-new-heart-pump-from-abiomed/
FDA Approves New Heart Pump From AbiomedAbiomed has announced that it received FDA approval for its Impella RP System, the first percutaneous single access heart pump that provides support to the right side of the heart. The approval, under a Humanitarian Device Exemption (HDE), is based on results of the single arm Recover Right study, in which 30 patients [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/28/fda-approves-new-heart-pump-from-abiomed/Wed, 28 Jan 2015 16:47:00 -0500Abiomed has announced that it received FDA approval for its Impella RP System, the first percutaneous single access heart pump that provides support to the right side of the heart. The approval, under a Humanitarian Device Exemption (HDE), is based on results of the single arm Recover Right study, in which 30 patients [...]http://www.forbes.com/sites/larryhusten/2015/01/27/can-precision-medicine-do-better-than-precision-weather/
Can Precision Medicine Do Better Than Precision Weather?(Updated) Looking out of my New York City window this morning at the meager 6 inches of snow on the ground I can't help wondering if precision medicine in the foreseeable future will be able to do a better job than precision weather forecasting today. Weather forecasters, using all the tools of modern science, blew [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/27/can-precision-medicine-do-better-than-precision-weather/Tue, 27 Jan 2015 10:22:00 -0500(Updated) Looking out of my New York City window this morning at the meager 6 inches of snow on the ground I can't help wondering if precision medicine in the foreseeable future will be able to do a better job than precision weather forecasting today. Weather forecasters, using all the tools of modern science, blew [...]http://www.forbes.com/sites/larryhusten/2015/01/26/califf-to-leave-duke-to-become-fda-deputy-commissioner/
Califf To Leave Duke To Become FDA Deputy CommissionerThe FDA announced today that Duke University cardiologist Robert Califf will be the next FDA Deputy Commissioner for Medical Products and Tobacco. The agency said that Califf will be responsible for the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/26/califf-to-leave-duke-to-become-fda-deputy-commissioner/Mon, 26 Jan 2015 14:13:00 -0500The FDA announced today that Duke University cardiologist Robert Califf will be the next FDA Deputy Commissioner for Medical Products and Tobacco. The agency said that Califf will be responsible for the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health [...]http://www.forbes.com/sites/larryhusten/2015/01/26/sanofi-and-regeneron-leapfrog-amgen-in-new-cholesterol-drug-race/
Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug RaceEarly on Monday Sanofi and Regeneron leapfrogged their rival Amgen to gain leadership in the race to bring a new class of cholesterol drugs to market. The new development could potentially give Sanofi and Regeneron a month on the market by itself before facing competition from Amgen. Sanofi and Regeneron announced early on Monday that [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/26/sanofi-and-regeneron-leapfrog-amgen-in-new-cholesterol-drug-race/Mon, 26 Jan 2015 02:46:00 -0500Early on Monday Sanofi and Regeneron leapfrogged their rival Amgen to gain leadership in the race to bring a new class of cholesterol drugs to market. The new development could potentially give Sanofi and Regeneron a month on the market by itself before facing competition from Amgen. Sanofi and Regeneron announced early on Monday that [...]http://www.forbes.com/sites/larryhusten/2015/01/23/salt-science-and-the-american-heart-associations-double-standard/
Salt, Science And The American Heart Association's Double StandardOnce again the American Heart Association is sticking by its recommendation that pretty much everyone should consume no more than 1,500 milligrams of sodium each day. This is dramatically lower than the 3,500 mg/d the average American now consumes. In a blog post reprinted on MedPage Today the president of the American [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/23/salt-science-and-the-american-heart-associations-double-standard/Fri, 23 Jan 2015 11:48:00 -0500Once again the American Heart Association is sticking by its recommendation that pretty much everyone should consume no more than 1,500 milligrams of sodium each day. This is dramatically lower than the 3,500 mg/d the average American now consumes. In a blog post reprinted on MedPage Today the president of the American [...]http://www.forbes.com/sites/larryhusten/2015/01/22/new-device-to-lower-resistant-high-blood-pressure-shows-early-promise/
New Device To Lower Resistant High Blood Pressure Shows Early Promise(Updated) A novel implantable device appears to show early promise in the treatment of resistant hypertension. The "Coupler" device from privatelyheld ROX Medical is about the size of a paper clip and is delivered via a catheter to the upper thigh, where it creates a connection between the vein and the artery, which [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/22/new-device-to-lower-resistant-high-blood-pressure-shows-early-promise/Thu, 22 Jan 2015 19:47:00 -0500(Updated) A novel implantable device appears to show early promise in the treatment of resistant hypertension. The "Coupler" device from privatelyheld ROX Medical is about the size of a paper clip and is delivered via a catheter to the upper thigh, where it creates a connection between the vein and the artery, which [...]http://www.forbes.com/sites/larryhusten/2015/01/22/why-doctors-like-airline-pilots-should-not-be-completely-trusted/
Why Doctors, Like Airline Pilots, Should Not Be Completely TrustedI would never get on an airplane if I didn't feel highly confident that the pilot was fully competent. In order to fly a commercial airplane a pilot has to undergo rigorous and continuous training and testing. I'd walk before flying with a pilot whose only credential was his assurance that [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/22/why-doctors-like-airline-pilots-should-not-be-completely-trusted/Thu, 22 Jan 2015 10:58:00 -0500I would never get on an airplane if I didn't feel highly confident that the pilot was fully competent. In order to fly a commercial airplane a pilot has to undergo rigorous and continuous training and testing. I'd walk before flying with a pilot whose only credential was his assurance that [...]http://www.forbes.com/sites/larryhusten/2015/01/20/get-up-offa-that-thing-intense-exercise-doesnt-eliminate-the-hazard-of-intense-sitting/
Get Up Offa That Thing: Intense Exercise Doesn't Eliminate The Hazard Of Intense SittingJames Brown had it right. There may be no better medical advice these days than to "Get Up Offa That Thing." A large new analysis published in Annals of Internal Medicine supports earlier observations that the health hazards of sedentary behavior aren't completely neutralized by exercise. Researchers in Toronto scoured the literature to find [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/20/get-up-offa-that-thing-intense-exercise-doesnt-eliminate-the-hazard-of-intense-sitting/Tue, 20 Jan 2015 09:21:00 -0500James Brown had it right. There may be no better medical advice these days than to "Get Up Offa That Thing." A large new analysis published in Annals of Internal Medicine supports earlier observations that the health hazards of sedentary behavior aren't completely neutralized by exercise. Researchers in Toronto scoured the literature to find [...]http://www.forbes.com/sites/larryhusten/2015/01/19/how-much-salt-should-old-people-consume/
How Much Salt Should Old People Consume?A new study offers fresh evidence that current salt recommendations should be taken with, well, a grain of salt. Current guidelines now recommend that everyone should have sodium intake levels below 2300 mg per day. For many people at higher risk, including everyone over 50 years of age, sodium intake [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/19/how-much-salt-should-old-people-consume/Mon, 19 Jan 2015 11:26:00 -0500A new study offers fresh evidence that current salt recommendations should be taken with, well, a grain of salt. Current guidelines now recommend that everyone should have sodium intake levels below 2300 mg per day. For many people at higher risk, including everyone over 50 years of age, sodium intake [...]http://www.forbes.com/sites/larryhusten/2015/01/14/hidden-clinical-trial-data-the-dam-is-about-to-burst/
Buried Clinical Trial Data: The Dam Is About To BurstTwo important new developments may mean that many more researchers will soon be able to access and analyze data from many more clinical trials. In recent years, in response to troubling and far-reaching questions about the availability and reliability of clinical trial data, reformers have called for new policies that would [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/14/hidden-clinical-trial-data-the-dam-is-about-to-burst/Wed, 14 Jan 2015 17:01:00 -0500Two important new developments may mean that many more researchers will soon be able to access and analyze data from many more clinical trials. In recent years, in response to troubling and far-reaching questions about the availability and reliability of clinical trial data, reformers have called for new policies that would [...]http://www.forbes.com/sites/larryhusten/2015/01/14/astrazeneca-drug-improves-outcomes-after-heart-attacks/
AstraZeneca Drug Improves Outcomes After Heart AttacksFor the first time a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients one to three years after a heart attack. Because it has been shown previously to reduce the high risk of recurrent events for up to a year following a heart attack, [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/14/astrazeneca-drug-improves-outcomes-after-heart-attacks/Wed, 14 Jan 2015 14:31:00 -0500For the first time a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients one to three years after a heart attack. Because it has been shown previously to reduce the high risk of recurrent events for up to a year following a heart attack, [...]http://www.forbes.com/sites/larryhusten/2015/01/13/success-for-40-year-effort-in-one-rural-county-to-curb-cardiovascular-disease/
Success For 40-Year Effort In One Rural County To Curb Cardiovascular DiseaseA 40-year program in one poor rural county to combat cardiovascular disease appears to have been successful, resulting in reduced rates of hospitalization and death compared with other counties in the same state over the same time period. The new findings from the study are described in a paper published in the Journal [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/13/success-for-40-year-effort-in-one-rural-county-to-curb-cardiovascular-disease/Tue, 13 Jan 2015 11:05:00 -0500A 40-year program in one poor rural county to combat cardiovascular disease appears to have been successful, resulting in reduced rates of hospitalization and death compared with other counties in the same state over the same time period. The new findings from the study are described in a paper published in the Journal [...]http://www.forbes.com/sites/larryhusten/2015/01/12/millions-of-americans-taking-aspirin-when-they-shouldnt/
Millions Of Americans Taking Aspirin When They Shouldn'tMore than a third of US adults-- more than 50 million people-- now take aspirin for the primary and secondary prevention of cardiovascular disease. (Primary prevention is the prevention of a first event; secondary prevention is the prevention of a recurrent event.) Although it was once broadly recommended, because of [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/12/millions-of-americans-taking-aspirin-when-they-shouldnt/Mon, 12 Jan 2015 16:14:00 -0500More than a third of US adults-- more than 50 million people-- now take aspirin for the primary and secondary prevention of cardiovascular disease. (Primary prevention is the prevention of a first event; secondary prevention is the prevention of a recurrent event.) Although it was once broadly recommended, because of [...]http://www.forbes.com/sites/larryhusten/2015/01/12/more-turmoil-for-troubled-medical-laboratory-company/
More Turmoil For Troubled Medical Laboratory CompanyProblems continue to accumulate for the deeply troubled medical laboratory company Health Diagnostic Laboratory. Following several years of spectacular growth, in which the company grew to $400 million in annual revenue, the company last year began an equally spectacular implosion when it became known that the federal government was investigating the company for giving kickbacks [...]Larry Husten, Contributorhttp://www.forbes.com/sites/larryhusten/2015/01/12/more-turmoil-for-troubled-medical-laboratory-company/Mon, 12 Jan 2015 13:41:00 -0500Problems continue to accumulate for the deeply troubled medical laboratory company Health Diagnostic Laboratory. Following several years of spectacular growth, in which the company grew to $400 million in annual revenue, the company last year began an equally spectacular implosion when it became known that the federal government was investigating the company for giving kickbacks [...]